SB-01 For Injection — Competitive Intelligence Brief

SB-01 For Injection (SB-01 For Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bone graft substitute. Area: Orthopedics.

phase 3 Bone graft substitute Orthopedics Small molecule

Target snapshot

SB-01 For Injection (SB-01 For Injection) — Spine BioPharma, Inc. SB-01 For Injection is a bone graft substitute used to promote bone growth and healing.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SB-01 For Injection TARGET	SB-01 For Injection	Spine BioPharma, Inc	phase 3	Bone graft substitute
Bioceramic putty	Bioceramic putty	Mohamed Salah Elwakeel	marketed	Biocompatible ceramic material / bone graft substitute
calcium phosphosilicate putty alloplast graft	calcium phosphosilicate putty alloplast graft	University of Louisville	marketed	Bone graft substitute
BioMend without ReproBone	BioMend without ReproBone	University of Sao Paulo	marketed	Bone graft substitute
bone substitute	bone substitute	Al-Azhar University	marketed	Bone graft substitute / Biomaterial
bone substitute i-FactorTM	bone substitute i-FactorTM	Istituto Ortopedico Rizzoli	marketed	Bone graft substitute / Osteoinductive biomaterial	Bone morphogenetic protein signaling pathway
Bio-Oss	Bio-Oss	Mohanad Al-Sabbagh	phase 3	Bone graft substitute

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bone graft substitute class)

1. Mohanad Al-Sabbagh · 1 drug in this class
2. Spine BioPharma, Inc · 1 drug in this class
3. University of Louisville · 1 drug in this class
4. University of Sao Paulo · 1 drug in this class